GlobeNewswire 2021-10-26 BioCryst to Present New ORLADEYO® (berotralstat) Data at Annual Scientific Meeting of American Colle...
GlobeNewswire 2021-10-20 BioCryst to Report Third Quarter 2021 Financial Results on November 3
GlobeNewswire 2021-10-04 ProQR Appoints Theresa Heggie as Chief Commercial Officer
GlobeNewswire 2021-10-04 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 2021-09-20 BioCryst Appoints Dr. Amy McKee to Board of Directors
GlobeNewswire 2021-09-16 NICE Recommends BioCryst’s ORLADEYO® (berotralstat), the First Oral, Once-daily Therapy, to Prevent ...
GlobeNewswire 2021-09-09 BioCryst Announces Approval of ORLADEYO® (berotralstat) in United Arab Emirates
GlobeNewswire 2021-09-03 BioCryst to Present at Upcoming Investor Conferences
GlobeNewswire 2021-09-02 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 2021-09-01 U.S. Government Exercises Option to Purchase Additional RAPIVAB® (peramivir injection) from BioCryst...
GlobeNewswire 2021-08-26 BioCryst Appoints Dr. Steven Galson to Board of Directors
GlobeNewswire 2021-08-25 BioCryst Announces Acceptance of Regulatory Applications for ORLADEYO® (berotralstat) by Health Cana...
GlobeNewswire 2021-08-11 BioCryst Withdraws Public Offering
GlobeNewswire 2021-08-09 BioCryst Commences Public Offering of Common Stock and Pre-Funded Warrants
GlobeNewswire 2021-08-05 BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones
GlobeNewswire 2021-08-03 BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 2021-07-28 BioCryst Appoints Vincent Milano to Board of Directors
GlobeNewswire 2021-07-22 BioCryst to Report Second Quarter 2021 Financial Results on August 5
GlobeNewswire 2021-07-15 BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy...
GlobeNewswire 2021-07-10 BioCryst Reports 96-week Data from APeX-2 Showing ORLADEYO®(berotralstat) Reduced HAE Attack Rate by...
GlobeNewswire 2021-07-01 ORLADEYO™ (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology...
GlobeNewswire 2021-06-16 BioCryst Announces Acceptance and Accelerated Review of the ORLADEYO™ (berotralstat) Marketing Appli...
GlobeNewswire 2021-06-03 BioCryst Launches ORLADEYO™ (berotralstat) in Germany
GlobeNewswire 2021-05-26 BioCryst to Present at Upcoming Investor Conferences
GlobeNewswire 2021-05-12 BioCryst Receives UK Approval of ORLADEYO™ (berotralstat), First Oral, Once-daily Therapy to Prevent...